Molecular Assemblies Appoints NuVasive Executive Sean Freeman to Board of Directors

News provided by

Jun 15, 2017, 07:30 ET

SAN DIEGO, June 15, 2017 /PRNewswire/ -- Molecular Assemblies Inc., a company developing a proprietary enzymatic DNA synthesis technology, today announced that it has expanded its board of directors with the appointment of Sean Freeman, NuVasive head of strategy and corporate development, to its board of directors.

"Sean's extensive business development experience in both strategic partnerships and mergers and acquisitions (M&A) combined with his financial acumen will serve Molecular Assemblies well as we further develop and commercialize our enzymatic DNA synthesis technology," said Molecular Assemblies President and CEO Michael J. Kamdar. "We are excited to welcome Sean to our board."

Mr. Freeman brings to Molecular Assemblies more than 20 years' experience securing licensing deals and strategic partnerships, and in international deal making. He has closed more than $100 billion in transactions in various capacities as a venture investor, investment banker, and corporate M&A lead. As head of strategy and corporate development for NuVasive, Mr. Freeman oversees the company's inorganic activity, including the management of its strategic venture portfolio. Mr. Freeman previously worked as senior vice president of business development for Cole-Parmer Instrument Company, and as head of corporate ventures and M&A at Life Technologies, a leading multinational life sciences company that was acquired by Thermo Fisher Scientific. Previously, Mr. Freeman was an investment banker in Merrill Lynch's Mergers & Acquisitions Group in New York. He earned a Master of Business Administration degree at the Wharton School and holds a Chartered Financial Analyst designation.

"Molecular Assemblies' enzymatic approach to developing long, high-quality DNA represents an exciting and meaningful advance in DNA synthesis - one that may hold the key to delivering the promise of genetic engineering and enabling tomorrow's innovations - from new vaccines to biofuels to information storage and beyond," Mr. Freeman said. "I am pleased to join the board, and look forward to working with a highly talented team to further grow the company."

"We are very pleased to welcome Sean to our board and look forward to benefitting from his significant experience and to his contributions to our team," said Board Chairman Larry Stambaugh.

About Molecular Assemblies

Molecular Assemblies, Inc. is a San Diego-based company focused on developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably and sustainably. Molecular Assemblies' technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines and bio-based electronics. For more information please visit molecularassemblies.com.